Membranoproliferative glomerulonephritis laboratory findings: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) |
||
| Line 38: | Line 38: | ||
*A positive [[ANA]], anti [[DsDNA virus|dsDNA]] suggest the diagnosis of membranous glomerulonephritis | *A positive [[ANA]], anti [[DsDNA virus|dsDNA]] suggest the diagnosis of membranous glomerulonephritis | ||
*To confirm the diagnosis we do [[renal biopsy]] | *To confirm the diagnosis we do [[renal biopsy]] | ||
=== Complement profile - === | === Complement profile - === | ||
* MPGN type I<ref name="pmid18408474">{{cite journal| author=Alpers CE, Smith KD| title=Cryoglobulinemia and renal disease. | journal=Curr Opin Nephrol Hypertens | year= 2008 | volume= 17 | issue= 3 | pages= 243-9 | pmid=18408474 | doi=10.1097/MNH.0b013e3282f8afe2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18408474 }} </ref> | * MPGN type I<ref name="pmid18408474">{{cite journal| author=Alpers CE, Smith KD| title=Cryoglobulinemia and renal disease. | journal=Curr Opin Nephrol Hypertens | year= 2008 | volume= 17 | issue= 3 | pages= 243-9 | pmid=18408474 | doi=10.1097/MNH.0b013e3282f8afe2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18408474 }} </ref> | ||
Latest revision as of 20:21, 6 August 2018
|
Membranoproliferative glomerulonephritis Microchapters |
|
Differentiating Membranoproliferative glomerulonephritis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Membranoproliferative glomerulonephritis laboratory findings On the Web |
|
American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis laboratory findings |
|
FDA on Membranoproliferative glomerulonephritis laboratory findings |
|
CDC on Membranoproliferative glomerulonephritis laboratory findings |
|
Membranoproliferative glomerulonephritis laboratory findings in the news |
|
Blogs on Membranoproliferative glomerulonephritis laboratory findings |
|
Directions to Hospitals Treating Membranoproliferative glomerulonephritis |
|
Risk calculators and risk factors for Membranoproliferative glomerulonephritis laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Jogeet Singh Sekhon, M.D. [2]
Overview
MPGN laboratory findings include urinalysis, renal function tests, complete blood counts, complement profile and other diagnostic tests for evaluating the cause of MPGN.
Laboratory Findings
Urinalysis
- Glomerular hematuria; characterized by dysmorphic red blood cells (RBCs) and RBC casts[1]
- Proteinuria is almost always present.
- Urine protein creatinine ratio is a good estimate of 24-hour urinary protein excretion.
- Nephrotic proteinuria is present in approximately 50% of patients.
Serum chemistries
- Elevated serum creatinine and blood urine nitrogen and a decreased estimated glomerular filtration rate (GFR) are evident in 20-50% of patients at presentation. Patients with a nephritic presentation typically have a decreased GFR[2].
- Hyperlipidemia and low albumin may be seen with nephrotic syndrome.
CBC with differential:
- Most often, patients have a normocytic normochromic anemia
Urine analysis
- May show proteinuria
Renal function tests
- Serum creatinine and BUN might be elevated
Complement profile
- C3, C4 and CH50 levels for classic complement pathway
- AH50 levels for alternate complement pathway
- C3 nephritic factor levelsj[3]
Serum ANA
- Postive serum ANA means autoimmune disease etiology
Blood culture
- Chronic bacterial infections
Sequence of Diagnostic Studies
The urinalysis and comprehensive chemistry panel should be performed when:[4]
- The patient presented with signs of hypertension and proteinurea
- Complete blood count
- Urinaylsis
- A positive ANA, anti dsDNA suggest the diagnosis of membranous glomerulonephritis
- To confirm the diagnosis we do renal biopsy
Complement profile -
- MPGN type I[5]
- C3 levels are low in about half of the patients.
- Evidence of activation of the classic pathway of complement (ie, low C4, C2, C1q, B, C3)
- Terminal complement components C3, C5, C8, and C9 may be low or within the reference range.
- NFc (C4NeF) or NFt may be present.
- MPGN type II
- C3 levels are low in 70-80% of patients.
- Early and terminal complement components are within the reference range.
- NFa (C3NeF) is present in more than 70% of patients.
- MPGN type III
- C3 levels are decreased in 50% of patients.
- C1q and C4 levels are within the reference range.
- Terminal complement components are low, especially if C3 is markedly depressed.
- NFa is absent and NFt is present in 60-80% of patients.
- Antistreptolysin-O (ASO) titers may be elevated in as many as 50% of patients at presentation.
- To rule out secondary causes, obtain antinuclear antibodies, hepatitis screens, cryoglobulins, urine, and serum protein electrophoresis.
References
- ↑ Sethi S, Fervenza FC (2012). "Membranoproliferative glomerulonephritis--a new look at an old entity". N Engl J Med. 366 (12): 1119–31. doi:10.1056/NEJMra1108178. PMID 22435371.
- ↑ Rennke HG (1995). "Secondary membranoproliferative glomerulonephritis". Kidney Int. 47 (2): 643–56. PMID 7723253.
- ↑ Bourke E, Campbell WG, Piper M, Check IJ (1989). "Hypocomplementemic proliferative glomerulonephritis with C3 nephritic-factor-like activity in multiple myeloma". Nephron. 52 (3): 231–7. doi:10.1159/000185648. PMID 2662048.
- ↑ Qin W, Beck LH, Zeng C, Chen Z, Li S, Zuo K, Salant DJ, Liu Z (June 2011). "Anti-phospholipase A2 receptor antibody in membranous nephropathy". J. Am. Soc. Nephrol. 22 (6): 1137–43. doi:10.1681/ASN.2010090967. PMC 3103733. PMID 21566055.
- ↑ Alpers CE, Smith KD (2008). "Cryoglobulinemia and renal disease". Curr Opin Nephrol Hypertens. 17 (3): 243–9. doi:10.1097/MNH.0b013e3282f8afe2. PMID 18408474.